Bleyzac N - Search Results

1

Azithromycin for COVID-19: More Than Just an Antimicrobial?

Bleyzac N, Goutelle S, Bourguignon L, Tod M. Bleyzac N, et al. Clin Drug Investig. 2020 Aug;40(8):683-686. doi: 10.1007/s40261-020-00933-3. Clin Drug Investig. 2020. PMID: 32533455 Free PMC article. No abstract available.

2

Oral voriconazole dose in children: one size does not fit all.

Goutelle S, Larcher R, Padoin C, Mialou V, Bleyzac N. Goutelle S, et al. Among authors: bleyzac n. Clin Infect Dis. 2010 Oct 1;51(7):870; author reply 871. doi: 10.1086/656293. Clin Infect Dis. 2010. PMID: 20809842 No abstract available.

3

Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model.

Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M. Gérard C, et al. Among authors: bleyzac n. Pharm Res. 2010 Dec;27(12):2602-13. doi: 10.1007/s11095-010-0252-1. Epub 2010 Sep 2. Pharm Res. 2010. PMID: 20811933

4

Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model.

Gérard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M. Gérard C, et al. Among authors: bleyzac n. Pharm Res. 2011 Mar;28(3):531-9. doi: 10.1007/s11095-010-0299-z. Epub 2010 Oct 21. Pharm Res. 2011. PMID: 20963627

5

Comment: assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.

Goutelle S, Neely M, Bleyzac N. Goutelle S, et al. Among authors: bleyzac n. Ann Pharmacother. 2011 Sep;45(9):1171-2. doi: 10.1345/aph.1P588a. Epub 2011 Aug 23. Ann Pharmacother. 2011. PMID: 21862712 No abstract available.

6

The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study.

Bourguignon L, Ducher M, Matanza D, Bleyzac N, Uhart M, Odouard E, Maire P, Goutelle S. Bourguignon L, et al. Among authors: bleyzac n. Fundam Clin Pharmacol. 2012 Apr;26(2):279-85. doi: 10.1111/j.1472-8206.2011.01000.x. Epub 2011 Oct 17. Fundam Clin Pharmacol. 2012. PMID: 22004557

7

A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection.

Janoly-Dumenil A, Rouvet I, Bleyzac N, Morfin F, Zabot MT, Tod M. Janoly-Dumenil A, et al. Among authors: bleyzac n. Antimicrob Agents Chemother. 2012 Jul;56(7):3732-8. doi: 10.1128/AAC.06423-11. Epub 2012 Apr 23. Antimicrob Agents Chemother. 2012. PMID: 22526305 Free PMC article.

8

In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.

Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M. Goutelle S, et al. Among authors: bleyzac n. AAPS J. 2013 Apr;15(2):415-26. doi: 10.1208/s12248-012-9431-9. Epub 2013 Jan 15. AAPS J. 2013. PMID: 23319287 Free PMC article.

9

Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.

Castellan AC, Tod M, Gueyffier F, Audars M, Cambriels F, Kassaï B, Nony P; Genophar Working Group. Castellan AC, et al. Clin Pharmacokinet. 2013 Mar;52(3):199-209. doi: 10.1007/s40262-013-0031-3. Clin Pharmacokinet. 2013. PMID: 23344982

10

Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile.

Bleyzac N, Kebaili K, Mialou V, Bertrand Y, Goutelle S. Bleyzac N, et al. Ther Drug Monit. 2014 Dec;36(6):724-9. doi: 10.1097/FTD.0000000000000084. Ther Drug Monit. 2014. PMID: 24739665

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

106 results

Search Page